Therapeutic Development Services
Anaplastic large cell lymphoma (ALCL) is an uncommon type of lymphoma that is difficult to treat. To untangle the multifaceted problems of treating ALCL, Protheragen has devoted advanced technologies and skilled personnel in the development of novel therapeutics. The support services we offer will greatly expedite your journey from a drug candidate to market launch.
Anaplastic large cell lymphoma (ALCL) is categorized as both rare and aggressive due to its nature as a T-cell non-Hodgkin lymphoma. It is characterized by CD30+ malignant cells with hallmark cells and is primarily sub-divided into two forms: ALK positive (70% of cases) and ALK negative (30% of cases). Patients with ALK ALCL usually manifest with lymphadenopathy, systemic B symptoms, and marked extranodal involvement.
Fig.1 Cell morphology in anaplastic large cell lymphoma (ALCL). (Tabbó, Fabrizio, et al., 2012)
The pathogenesis of anaplastic large cell lymphoma (ALCL) is closely linked to genetic alterations and dysregulation of signaling pathways.
ALK Gene Mutation
One of the key genetic abnormalities associated with ALCL is the translocation involving the ALK (Anaplastic Lymphoma Kinase) gene, leading to the expression of the ALK protein. The fusion of ALK with various partner genes results in constitutive activation of ALK signaling, promoting cell growth and survival.
Dysregulated Signaling Pathways
The activated ALK protein triggers downstream signaling pathways, such as the JAK/STAT, PI3K/AKT/mTOR, and MAPK/ERK pathways, which play essential roles in promoting cell proliferation, inhibiting apoptosis, and enhancing cell migration. Dysregulation of these pathways contributes to the uncontrolled growth of malignant lymphoid cells in ALCL.
Other Gene Mutations
In ALK-negative cases of ALCL, other genetic alterations and signaling pathway abnormalities are often observed. These may involve mutations in genes such as TP53, JAK1, or STAT3, leading to oncogenic transformation and tumor progression. The tumor microenvironment in ALCL also plays a crucial role in disease pathogenesis.
The therapeutic market for anaplastic large cell lymphoma (ALCL) is estimated to grow from USD 11.65 billion in 2024 to USD 16.75 billion by 2031. The absence of sustainable solutions for treating ALK-negative ALCL and developing resistance in ALK-positive ALCL cases to current treatments have increased interest in new targeted put through mechanisms of action and immunotherapy.
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| SGN-30 | Monoclonal antibody blocking CD30 signaling | CD30 | NCT00079755 | Phase II |
| LCAR-HL30 | CAR-T cell therapy targeting CD30 | CD30 | NCT06494371 | Phase I |
| Denileukine Diftitox | Recombinant fusion protein combining IL-2 and diphtheria toxin to kill CD25+ cells | IL-2 receptor | NCT00801918 | Phase II |
| MDX-060 | Humanized monoclonal antibody blocking CD30 signaling | CD30 | NCT00298467 | Phase II |
| Brentuximab Vedotin and Bendamustine | Antibody-drug conjugate + alkylating chemotherapy | CD30 | NCT01657331 | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
To advance the effective management of anaplastic large cell lymphoma (ALCL), Protheragen provides full-service diagnostic and therapeutic development services. Aligned with the various molecular mechanisms of action underlying ALCL, we focus on developing innovative targeted therapies to address substantial medical gaps. Our specialists develop sophisticated disease models which allow for thorough assessment of the safety, effectiveness, and biologic action of the potential therapeutics.
Therapeutic Development Services
As a leading provider of therapeutic development services, Protheragen is focused on developing a variety of innovative therapies for anaplastic large cell lymphoma (ALCL) to address the complex challenges in this field.
We specialize in creating accurate animal models that replicate the features of anaplastic large cell lymphoma (ALCL). These models offer a controlled environment for conducting preclinical research of potential therapies.
At Protheragen, we offer comprehensive pharmacodynamic (PD), pharmacokinetic (PK), and toxicology research services to support the development and regulatory approval of potential therapies for anaplastic large cell lymphoma (ALCL). If you are interested in our services, please feel free to contact usfor more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
